Partial dopamine agonists in the treatment of psychosis

Journal of Neural Transmission

Volumn 109, Issue 3, 2002, Pages 411-420

  Tamminga, C A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

( ) 3PPP; Apomorphine; Dopamine; N propylnorapomorphine; Schizophrenia

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CLOZAPINE; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PARTIAL AGONIST; PRECLAMOL; PROPYLNORAPOMORPHINE;

ARTICLE; CLINICAL TRIAL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPOTENSION; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; APOMORPHINE; AUTORECEPTORS; BRAIN; DOPAMINE AGONISTS; HUMANS; PIPERIDINES; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE;

EID: 0036202379     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200033     Document Type: Article

References (38)

1. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
2. Affinity and intrinsic activity in the theory of competitive inhibition
3. Intrinsic activity: Partial agonists and partial antagonists
4. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression
5. Receptor mediated control of dopamine metabolism
6. Some aspects of dopamine in the basal ganglia
7. Dopamine receptor agonists: Intrinsic activity vs. state of receptor
8. 3-(3-Hydroxyphenyl)-N-n-Propylpiperdine (3-PPP): A novel tool for the characterization of dopamine receptors
9. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
10. Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity. I. Review of the evidence
11. Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations
12. The use of dopamine agonists in the treatments of schizophrenia
13. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone
14. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
15. Traitement de etats d'excitation et d'agitation par une methode medicamenteuse derivee de l'hibernotherapie
16. Apomorphine in agitation
17. Drug-induced changes in the release of 3 H-monoamines fromfield stimulated rat brain slices
18. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP
19. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity
20. Glutamic acid and schizophrenia: Potential pharmacological and therapeutic approaches
21. Antipsychotic properties of the partial dopamine agonist (-)-3PPP in schizophrenia
22. Presynaptic regulation of the release of catecholamines
23. Evidence for activation of dopaminergic autoreceptors by (-)3-PPP
24. Phase I study of a new antipsychotic drug, OPC-4392
25. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia
26. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907
27. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
28. Suppression of exploratory locomotor activity in the rat by the local application of 3-PPP enantiomers into the nucleus accumbens
29. Antipsychotic and antidyskinetic properties of ergot dopamine agonists
30. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine
31. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia
32. Schizophrenic symptoms improve with apomorphine
33. Pharmacologic properties of (-)-3PPP (preclamol) in man
34. Neuropsychiatric aspects of schizophrenia
35. Piribedil and apomorphine: Pre- and postsynaptic effects on dopamine synthesis and neuronal activity
36. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms